Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary disease
Doctors found that bladder cancer returning later has higher risk of coming back again
This systematic review and meta-analysis of 1292 patients found that metachronous non-muscle invasive bladder cancer after upper tract uroth…
A large review shows bladder cancer returning after a previous kidney cancer treatment is more likely to grow back. This group also has a lo…
Systematic review and meta-analysis on BCG lymphadenitis incidence in healthy children
A review of one point eight million children shows BCG vaccine side effects vary greatly depending on how doctors watch for them
This systematic review and meta-analysis synthesized data on BCG lymphadenitis incidence in healthy children. The pooled incidence proportio…
This large review looked at swelling near the injection site in healthy kids given the BCG vaccine. The chance of this happening changed a l…
Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer
A Common Bladder Cancer Treatment Extends Remission, But at a Cost
This randomized controlled trial compared adjuvant intravesical BCG and Epirubicin in 122 patients with intermediate-risk non-muscle invasiv…
For a common bladder cancer, one treatment keeps the disease away longer, but the other may offer a better daily life.